公开(公告)号：US20230338528A1

公开(公告)日：2023-10-26

申请号：US18311108

申请日：2023-05-02

Applicant: Hangzhou Qihan Biotech Co., Ltd.

Inventor： Yangbin Gao ,  Xiangjun He ,  Yixuan Zhou ,  Chenyang Liao ,  Jiabiao Hu ,  Jing Xu ,  Yanan Yue ,  Luhan Yang

IPC: A61K39/00 ,  C07K14/54 ,  C07K16/42 ,  C07K14/47 ,  C07K14/705 ,  C07K14/74 ,  C07K14/715 ,  C07K14/735 ,  C07K14/495 ,  C12N9/12 ,  C12N9/16 ,  C12N9/48

CPC classification number: A61K39/4613 ,  A61K39/464402 ,  A61K39/4622 ,  A61K39/464411 ,  C07K14/5443 ,  A61K39/4644 ,  A61K39/464462 ,  A61K39/464419 ,  C07K16/4291 ,  A61K39/46444 ,  A61K39/464463 ,  C07K14/47 ,  A61K39/464454 ,  C07K14/70575 ,  A61K39/464412 ,  A61K39/464429 ,  C07K14/70539 ,  C07K14/70571 ,  A61K39/464434 ,  C07K14/715 ,  C07K14/70596 ,  C07K14/70525 ,  C07K14/70532 ,  C07K14/70578 ,  A61K39/4621 ,  A61K39/4631 ,  A61K39/4637 ,  A61K39/4635 ,  C07K14/70535 ,  C07K14/495 ,  C07K14/7155 ,  C07K14/54 ,  C07K14/70503 ,  C07K14/4748 ,  C07K14/5428 ,  C12N9/12 ,  C12Y207/11022 ,  C12N9/16 ,  C12Y301/03036 ,  C12Y301/03048 ,  C12N9/485 ,  C12Y304/11015 ,  A61K2239/23

Abstract: The present disclosure describes systems and methods for immunotherapies Immune cells can be engineered to exhibit enhanced half-life as compared to control cell (e.g., a non-engineered immune cell). Immune cells can be engineered to exhibit enhanced proliferation as compared to a control cell. Immune cells can be engineered to effectively and specifically target diseased cells (e.g., cancer cells) that a control cell otherwise is insufficient or unable to target. The engineered Immune cells disclosed herein can be engineered ex vivo, in vitro, and in some cases, in vivo. The engineered Immune cells that are prepared ex vivo or in vitro can be administered to a subject in need thereof to treat a disease (e.g., myeloma or solid tumors). The engineered Immune cells can be autologous to the subject. Alternatively, the engineered immune cells can be allogeneic to the subject.

公开(公告)号：US11793867B2

公开(公告)日：2023-10-24

申请号：US16955436

申请日：2018-12-18

Applicant: BIONTECH US INC.

Inventor： Vikram Juneja

IPC: A61K39/00 ,  A61P35/00 ,  A61K35/17 ,  C07K14/47 ,  C07K14/725 ,  C07K4/12

CPC classification number: A61K39/001152 ,  A61K35/17 ,  A61K39/001114 ,  A61K39/001164 ,  A61P35/00 ,  C07K14/4748 ,  C07K14/7051 ,  A61K2039/5154 ,  A61K2039/572 ,  C07K4/12

Abstract: Disclosed herein relates to immunotherapeutic compositions comprising immunotherapeutic peptides comprising neoepitopes, polynucleotides encoding the immunotherapeutic peptides, antigen presenting cells comprising the immunotherapeutic peptides or polynucleotides, or T cell receptors specific for the neoepitopes. Also disclosed herein is use of the immunotherapeutic compositions.

公开(公告)号：US20230331864A1

公开(公告)日：2023-10-19

申请号：US18304843

申请日：2023-04-21

Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

Inventor： Marco RUELLA ,  Saar GILL ,  Carl H. JUNE ,  Avery D. POSEY ,  Daniel J. POWELL

IPC: C07K16/28 ,  C07K14/705 ,  A61P35/00 ,  A61P35/02 ,  C07K14/725 ,  A61K35/17 ,  A61K39/00 ,  C07K14/47 ,  A61K38/00

CPC classification number: C07K16/2896 ,  C07K14/70578 ,  C07K16/2803 ,  A61P35/00 ,  A61P35/02 ,  C07K14/70596 ,  C07K14/7051 ,  C07K16/2806 ,  A61K35/17 ,  C07K14/70507 ,  C07K2317/565 ,  A61K2039/505 ,  C07K14/4748 ,  A61K38/00 ,  C07K2319/30 ,  C07K2319/03 ,  C07K2317/622 ,  A61K2039/5158 ,  A61K2039/5156 ,  C07K2319/33 ,  C07K2317/92

Abstract: The present invention includes compositions and methods for treating T cell lymphomas and leukemias. In certain aspects, the compositions and methods include CAR T cells targeting CD2, CD5, or CD7 and modified cells wherein CD2, CD5, or CD7 has been knocked-out.

公开(公告)号：US11787846B2

公开(公告)日：2023-10-17

申请号：US16997197

申请日：2020-08-19

Applicant: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

Inventor： Walter J. Storkus ,  Michael S. Kinch

IPC: A61K38/17 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/705 ,  G01N33/50 ,  G01N33/569 ,  A61K39/00

CPC classification number: C07K14/4748 ,  A61K38/1793 ,  A61K39/0011 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/705 ,  G01N33/505 ,  G01N33/5091 ,  G01N33/56966 ,  G01N33/56972 ,  A61K2039/55566 ,  G01N2333/5409 ,  G01N2333/57

Abstract: EphA2 T-cell epitope are provided herein. The epitopes include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivatives thereof. The EphA2 T-cell epitopes are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient's immune responsiveness to EphA2. The epitopes also are useful in methods of modulating a patient's immune reactivity to EphA2, which has substantial utility as a treatment for cancers that overexpress EphA2, such as renal cell carcinoma (RCC). The EphA2 epitopes also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods.

公开(公告)号：US11779603B2

公开(公告)日：2023-10-10

申请号：US16313712

申请日：2017-06-30

Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Services ,  Loyola University of Chicago

Inventor： Richard W. Childs ,  Michael I. Nishimura ,  Elena A. Cherkasova

IPC: A61K35/17 ,  C07K14/725 ,  C12N15/85 ,  C07K14/47 ,  C07K14/005

CPC classification number: A61K35/17 ,  C07K14/7051 ,  C12N15/85 ,  C07K14/005 ,  C07K14/4748

Abstract: Disclosed herein are T cell receptors (TCRs) capable of binding an antigen expressed by renal cell carcinoma cells. In some examples, the TCRs include an α chain (such as SEQ ID NO: 2) and a β chain (such as SEQ ID NO: 3). Also disclosed herein are vectors including nucleic acids encoding the disclosed TCR α and/or β chains. Further disclosed are modified T cells expressing the TCRs. In some examples, the modified T cells are prepared by transducing T cells with a vector including nucleic acids encoding the TCR α chain and the TCR β chain. In some embodiments, methods include treating a subject with RCC, by obtaining a population of T cells, transducing the population of T cells with a vector including a nucleic acids encoding the TCR α chain and the TCR β chain, and administering a composition comprising the modified T cells to the subject.

公开(公告)号：US20230302109A1

公开(公告)日：2023-09-28

申请号：US18046670

申请日：2022-10-14

Applicant: The Francis Crick Institute Limited ,  Enara Bio Limited

Inventor： George KASSIOTIS ,  George YOUNG ,  Jan ATTIG ,  Ambrosius SNIJDERS ,  David PERKINS ,  Fabio MARINO ,  Ray JUPP ,  Magdalena VON ESSEN ,  Peter MASON ,  Nicola TERNETTE

IPC: A61K39/00 ,  C07K14/47 ,  A61P35/00

CPC classification number: A61K39/00119 ,  C07K14/4748 ,  A61P35/00 ,  A61K2039/876 ,  A61K2039/5158 ,  A61K2039/5154

Abstract: There are disclosed inter alia antigen pools which are useful in the treatment of cancer, particularly melanoma, especially cutaneous melanoma and uveal melanoma.

公开(公告)号：US11759509B2

公开(公告)日：2023-09-19

申请号：US16163067

申请日：2018-10-17

Applicant: Sumitomo Pharma Co., Ltd. ,  INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.

Inventor： Chiang Jia Li ,  Hitoshi Ban ,  Yukihiro Nishio ,  Masashi Goto ,  Toshio Nishihara ,  Yosuke Takanashi

IPC: A61K39/00 ,  A61K47/64 ,  C07K14/47 ,  C07K7/06 ,  C07K7/08 ,  C07K14/00

CPC classification number: A61K39/001153 ,  A61K39/00 ,  A61K47/646 ,  C07K7/06 ,  C07K7/08 ,  C07K14/00 ,  C07K14/4748 ,  A61K2039/55 ,  A61K2039/55511 ,  A61K2039/55566 ,  A61K2039/572 ,  A61K2039/64 ,  A61K2039/70

Abstract: A compound represented by the formula (1):




wherein Xa and Ya are each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, R1 is a hydrogen atom, a group represented by the formula (2):





wherein Xb and Yb are each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.

公开(公告)号：US20230287071A1

公开(公告)日：2023-09-14

申请号：US18189443

申请日：2023-03-24

Applicant: Immatics Biotechnologies GmbH

Inventor： Colette SONG ,  Heiko SCHUSTER ,  Daniel Johannes KOWALEWSKI ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Toni WEINSCHENK ,  Harpreet SINGH

IPC: C07K14/47 ,  A61K35/17 ,  A61K39/00 ,  C07K14/725 ,  C07K14/74 ,  C07K16/18 ,  C12N5/0783 ,  C12Q1/6886

CPC classification number: C07K14/4748 ,  A61K35/17 ,  A61K39/0011 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/18 ,  C12N5/0636 ,  C12Q1/6886 ,  G16B25/10

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230285461A1

公开(公告)日：2023-09-14

申请号：US18185649

申请日：2023-03-17

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Franziska HOFFGAARD ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Toni WEINSCHENK ,  Daniel Johannes KOWALEWSKI ,  Chih-Chiang TSOU

IPC: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/28 ,  C07K7/06 ,  C07K14/54 ,  A61P35/02 ,  A61K39/00 ,  A61K45/06 ,  C12N5/0783 ,  A61K39/12 ,  C07K16/24 ,  A61K39/395 ,  A61K38/08 ,  C07K14/47

CPC classification number: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/2818 ,  C07K7/06 ,  C07K14/5434 ,  A61P35/02 ,  A61K39/001102 ,  A61K45/06 ,  C12N5/0636 ,  A61K39/001114 ,  A61K39/001118 ,  A61K39/12 ,  C07K16/244 ,  A61K39/39558 ,  C07K16/2821 ,  A61K38/08 ,  C07K14/4748 ,  A61K2039/5156 ,  A61K45/05

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230285458A1

公开(公告)日：2023-09-14

申请号：US18048489

申请日：2022-10-21

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Janet PEPER ,  Philipp WAGNER ,  Hans-Georg RAMMENSEE

IPC: A61K35/17 ,  C07K14/47 ,  A61K39/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/725 ,  C07K16/30 ,  C12N15/115 ,  C12P21/02 ,  C12Q1/6881 ,  C12Q1/6886 ,  G01N33/574

CPC classification number: A61K35/17 ,  C07K14/4748 ,  A61K39/0011 ,  C07K7/06 ,  C07K7/08 ,  C07K14/4727 ,  C07K14/7051 ,  C07K16/30 ,  C12N15/115 ,  C12P21/02 ,  C12Q1/6881 ,  C12Q1/6886 ,  G01N33/57484 ,  A61K2039/5158 ,  C12N2310/16 ,  C12Q2600/136 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N2333/70539 ,  G01N2500/04

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.